What Is Medical Device Cybersecurity?

Scope of this page: what medical device cybersecurity is — the plain-language definition, why it became a formal FDA requirement, who it applies to, and how it differs from adjacent concepts like general IT security frameworks and FDA’s premarket submission mechanics. If you already know you’re preparing a 510(k) or PMA submission and need the section-by-section requirements, the deep-dive version of this topic is linked below — this page is the broader “what is this and why does it exist” answer.

What medical device cybersecurity means

Medical device cybersecurity is the practice of protecting connected or software-driven medical devices — and the data they collect, store, or transmit — from security vulnerabilities that could compromise the device’s safety or effectiveness. It covers the full device lifecycle: how a device is designed and built to resist attack (secure development), how known and newly discovered vulnerabilities are tracked and patched after the device is on the market (postmarket vulnerability management), and how manufacturers document what software components are actually inside the device (a software bill of materials, or SBOM) so that a vulnerability in a third-party or open-source component can be found and fixed quickly.

The concern is not abstract. A modern medical device is frequently a small networked computer with a clinical function attached — an infusion pump, an implantable cardiac device, an imaging system, or a hospital monitoring platform, many of which connect to Wi-Fi, Bluetooth, or a hospital network to receive updates, transmit patient data, or be configured remotely. Any device with software, a network connection, and technological characteristics that could be exploited is, by definition, a target. A vulnerability in that kind of device is not just a data-privacy problem; it can directly threaten patient safety — an attacker who can alter a device’s function or disable it entirely is affecting the same “safety and effectiveness” standard FDA already regulates every device against for its intended clinical use.

Why it’s now a formal FDA requirement, not just good practice

Until 2023, cybersecurity was addressed in FDA guidance documents but was not an explicit statutory premarket requirement. That changed with the Consolidated Appropriations Act, 2023, which incorporated the PATCH Act language and added Section 524B of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. §360n-2, “Ensuring Cybersecurity of Devices”), effective roughly 90 days after the law’s December 29, 2022 enactment. It has applied to relevant premarket submissions for several years now — it is not a new or pending change.

Section 524B applies to a statutorily defined “cyber device”: a device that (1) includes software validated, installed, or authorized by the sponsor, (2) has the ability to connect to the internet, and (3) contains technological characteristics that could be vulnerable to cybersecurity threats. That third prong is intentionally broad — FDA reads it to reach most network-connected devices, not only devices that transmit patient data directly. For a device that meets the definition, a sponsor’s submission must include a plan to monitor, identify, and address postmarket vulnerabilities (including coordinated vulnerability disclosure and a commitment to timely patches), documentation of secure-development processes, an SBOM of the device’s software components, and anything else FDA reasonably requires to demonstrate reasonable assurance of cybersecurity.

FDA can exempt specific devices or device categories from these requirements by Federal Register notice, so not every device sold today is automatically in scope — but the default assumption for anything with network connectivity and onboard software is that it applies.

Who it applies to

The direct legal obligation sits with device manufacturers and sponsors submitting a premarket application (510(k), De Novo, or PMA) for a device that meets the “cyber device” definition. But the practical reach is wider than that:

• Manufacturers and sponsors building the secure-development processes, vulnerability-monitoring plans, and SBOMs the statute requires.
• Healthcare delivery organizations and research institutions that purchase, deploy, and operate connected devices — who inherit responsibility for network segmentation, patch management, and incident response once a device is in use, even though the premarket obligation belonged to the manufacturer.
• Clinical research teams using connected devices (wearables, remote monitoring platforms, connected infusion or diagnostic equipment) in trial protocols, who need to understand a device’s cybersecurity posture as part of data-integrity and participant-safety risk assessment.
• IT security, biomedical engineering, and procurement staff evaluating vendor devices before purchase, who increasingly ask vendors for an SBOM or a summary of their FDA cybersecurity submission as part of due diligence.

How it differs from adjacent concepts

Because “cybersecurity” and “medical device” both show up in several distinct contexts, it helps to draw the lines explicitly:

• Medical device cybersecurity vs. general IT/organizational cybersecurity. A framework like the NIST Cybersecurity Framework 2.0 addresses an organization’s overall security posture — identifying, protecting, detecting, responding to, and recovering from cyber risk across its people, processes, and systems generally. Medical device cybersecurity is narrower and product-specific: it’s about whether a particular device, as designed and shipped, resists compromise and can be patched. A research organization typically needs both — an institution-wide security framework and device-specific due diligence on the connected equipment it deploys.
• Medical device cybersecurity vs. FDA’s Section 524B premarket requirements specifically. Section 524B is the legal mechanism that made device cybersecurity a formal, enforceable part of premarket review — but it is the submission-mechanics layer (the cyber device test, the SBOM format, the secure product development framework, how cybersecurity risk analysis diverges from the ISO 14971 risk file). Medical device cybersecurity as a concept is broader than any one statute: it also includes postmarket practice, procurement due diligence, and clinical use considerations that exist independent of what a specific submission must contain.
• Medical device cybersecurity vs. general medical device regulation. A medical device, broadly defined, is any product intended to diagnose, treat, monitor, or prevent a disease or condition without doing so primarily through chemical action absorbed into the body — a category running from a tongue depressor to an implantable pacemaker. Cybersecurity is one specific safety dimension that applies only to the subset of devices with software and network connectivity, not to the category as a whole.

Where connectivity standards fit in

Devices don’t just need to resist attack — the data they exchange with electronic health record systems and monitoring platforms typically travels over established healthcare data-interoperability standards, most commonly HL7 and its modern successor FHIR. Securing that data in transit and at rest is part of the same overall device-security picture, even though HL7/FHIR themselves are interoperability standards rather than security frameworks.

Go deeper

• Already know you’re preparing a submission? See FDA Premarket Cybersecurity for Medical Devices: Section 524B, SBOM, and Threat Modeling for the section-by-section requirements, the cyber device test, and how cybersecurity risk analysis diverges from ISO 14971.
• Need the baseline regulatory definition of a device first? See What Is a Medical Device?
• Evaluating your organization’s broader security posture rather than a single device? See NIST Cybersecurity Framework 2.0: What It Actually Requires for a Federally Funded Research Lab.
• Working with the data-exchange standards connected devices typically use? See What Is HL7? and What Is FHIR?

Frequently asked questions

Is medical device cybersecurity legally required by FDA?

Yes, for devices that meet the statutory “cyber device” definition under Section 524B of the FD&C Act — software-containing, internet-connectable devices with exploitable technological characteristics. It has applied to relevant premarket submissions since roughly March 2023. FDA can exempt specific devices or categories by Federal Register notice.

What makes a device a “cyber device” under FDA’s definition?

Three conditions, all required: the device includes software validated, installed, or authorized by the sponsor; it can connect to the internet; and it has technological characteristics that could be vulnerable to cybersecurity threats. FDA interprets the third condition broadly, covering most network-connected devices rather than only those that transmit patient data.

Who is responsible for medical device cybersecurity in a research organization?

Manufacturers and sponsors carry the direct premarket legal obligation, but research institutions that deploy connected devices inherit real operational responsibility — network segmentation, patch management, incident response, and vendor due diligence — once a device is in use, particularly in clinical research settings using connected or remote-monitoring equipment.

Is medical device cybersecurity the same as general IT security?

No. General IT/organizational cybersecurity frameworks address an institution’s overall security posture across people, processes, and systems. Medical device cybersecurity is product-specific — whether a particular device, as designed, resists compromise and can be patched. Most research organizations need both.